natgillin/translations-raw huggingface dataset:
As for all medicines, data on the use of Ritemvia are continuously monitored.
Kao i za sve lijekove, podatci o primjeni lijeka Ritemvia kontinuirano se prate.
In GPA and MPA, destroying the B cells lowers the production of antibodies thought to play an important role in attacking the blood vessels and causing inflammation.
U bolesnika s bolestima GPA i MPA uništavanje B-stanica smanjuje proizvodnju protutijela za koja se smatra da imaju važnu ulogu u napadu na krvne žile i uzrokovanju upale.
Ritemvia must not be used in people who are hypersensitive (allergic) to rituximab, mouse proteins or any of the other ingredients.
Lijek Ritemvia ne smiju upotrebljavati osobe koje su preosjetljive (alergične) na rituksimab, mišje bjelančevine ili bilo koji drugi sastojak lijeka.
The reference medicine for Ritemvia is MabThera.
Referentni lijek za lijek Ritemvia je MabThera.
The company that markets Ritemvia will provide doctors and patients using the medicine for noncancer conditions with educational material including information on the need to give the medicine where facilities for resuscitation are available and on the risk of infection, including PML.
Tvrtka koja lijek Ritemvia stavlja u promet, liječnicima i bolesnicima koji primjenjuju lijek za bolesti koje nisu zloćudne dostavit će edukativni materijal, uključujući informacije o potrebi davanja lijeka na odjelima opremljenima aparatima za oživljavanje te o riziku od upale, uključujući PML.
Ritemvia can only be obtained with a prescription.
Ritemvia se izdaje samo na recept.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ritemvia have also been included in the summary of product characteristics and the package leaflet.
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Ritemvia nalaze se u sažetku opisa svojstava i u uputi o lijeku.
For more information about using Ritemvia, see the package leaflet or contact your doctor or pharmacist.
Za više informacija o primjeni lijeka Ritemvia pročitajte uputu o lijeku, odnosno obratite se liječniku ili ljekarniku.
Therefore, the Agency's view was that, as for MabThera, the benefits of Ritemvia outweigh the identified risks and it can be authorised for use in the EU.
Stoga je stav Agencije da, kao i kod lijeka MabThera, koristi od lijeka Ritemvia nadmašuju identificirane rizike te da lijek može biti odobren za primjenu u EU-u.
When rituximab attaches to CD20, it causes the death of B cells, which helps in lymphoma and CLL, where B cells have become cancerous.
Kad se rituksimab veže na bjelančevinu CD20, uzrokuje odumiranje B-stanica, što pomaže bolesnicima s limfomom i KLL-om kod kojih su B-stanice postale kancerogene.
The safety of Ritemvia has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine MabThera.
Ocijenjena je sigurnost primjene lijeka Ritemvia i na temelju svih provedenih ispitivanja nuspojave lijeka smatraju se usporedivima s onima za referentni lijek MabThera.
Ritemvia is a medicine used in adults to treat the following blood cancers and inflammatory conditions:
Ritemvia je lijek za liječenje sljedećih vrsta raka krvi i upala u odraslih bolesnika:
In addition, Ritemvia has been compared with MabThera given into a vein in a main study involving 372 patients with active rheumatoid arthritis (an inflammatory disease).
Nadalje, lijek Ritemvia uspoređen je s lijekom MabThera primjenom u venu u glavnom ispitivanju u kojem su sudjelovale 372 osobe koje boluju od reumatoidnog artritisa (upalna bolest).
It is available as a concentrate for making a solution that must be given by infusion (drip) into a vein.
Lijek je dostupan kao koncentrat za otopinu koja se daje kao infuzija (ukapavanje) u venu.
What benefits of Ritemvia have been shown in studies?
Koje su koristi od lijeka Ritemvia utvrđene u ispitivanjima?
Laboratory studies comparing Ritemvia with MabThera have shown that the active substance in Ritemvia is highly similar to that in MabThera in terms of structure, purity and biological activity.
Laboratorijska ispitivanja u kojem su uspoređivani lijekovi Ritemvia i MabThera pokazala su da je djelatna tvar u lijeku Ritemvia vrlo slična djelatnoj tvari u lijeku MabThera u pogledu strukture, čistoće i biološke aktivnosti.
All these data were considered sufficient to conclude that Ritemvia will behave in the same way as MabThera in terms of its effectiveness and safety in its authorised uses.
Svi ti podatci smatraju se dovoljnima za donošenje zaključka da će lijek Ritemvia za odobrene indikacije djelovati jednako kao lijek MabThera u pogledu učinkovitosti i sigurnosti primjene.
How does Ritemvia work?
Kako djeluje Ritemvia?
Studies have also shown that giving Ritemvia produces similar levels of the active substance in the body to giving MabThera.
Ispitivanja su pokazala i da primjena lijeka Ritemvia dovodi do slične razine djelatne tvari u tijelu kao i primjena lijeka MabThera.
In addition, a study comparing Ritemvia to MabThera in patients with rheumatoid arthritis (which can support its use in other inflammatory disorders such as GPA and MPA) showed that both medicines are similarly effective, and a supportive study in follicular lymphoma showed effectiveness in cancer.
Nadalje, ispitivanje u kojem su se usporedili lijekovi Ritemvia i MabThera u bolesnika s reumatoidnim artritisom (što podržava njihovu uporabu za druge upalne poremećaje, kao što su GPA i MPA) pokazalo je da je učinkovitost oba lijeka slična.
Ritemvia contains the active substance rituximab.
Ritemvia sadrži djelatnu tvar rituksimab.
Further evidence came from supportive studies including one involving 121 patients with advanced follicular lymphoma, where adding Ritemvia to chemotherapy medicines was at least as effective as adding Rituxan, the US version of MabThera.
Pokazalo se da je dodavanje lijeka Ritemvia lijekovima za kemoterapiju barem jednako učinkovito kao dodavanje lijeka Rituxan, američke verzije lijeka MabThera.
How is Ritemvia used?
Kako se Ritemvia primjenjuje?
For the full list of side effects of Ritemvia, see the package leaflet.
Potpuni popis zabilježenih nuspojava povezanih s lijekom Ritemvia potražite u uputi o lijeku.
Strength Pharmaceutical form Route of administration Packaging Package size EU/1/09/536/001 Topotecan Actavis 1 mg l t o r
Unutarnje pakovanje Veličina pakovanja EMEA/H/C/001031/0000/001 Topotecan Actavis 1 mg Prašak za koncentrat za otopinu za infuziju Za infuziju u venu bočica
You may take Levetiracetam Accord with or without food.
Levetiracetam Accord možete uzeti sa ili bez hrane.
Levetiracetam Accord must be taken twice a day, once in the morning and once in the evening, at about the same time each day.
Levetiracetam Accord se mora uzimati dva puta na dan, jednom ujutro i jednom navečer, u približno isto vrijeme svaki dan.
Elderly (65 years and older)
Starije osobe (65 godina i starije)
The film-coating contains:
Film ovojnica sadrži:
Date of first authorisation: 03rd October 2011 Date of latest renewal: 22nd July 2016
Datum posljednje obnove odobrenja: 22. srpanj 2016
This includes, any possible side effects not listed in this leaflet.
To uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi.
This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy).
To smanjenje koncentracije bilo je više izraženo tijekom trećeg trimestra (do 60% u odnosu na bazičnu koncentraciju prije trudnoće).
What Levetiracetam Accord is and what it is used for
Što je Levetiracetam Accord i za što se koristi
The lowest effective dose should be used.
Treba koristiti najmanju učinkovitu dozu.
current epidemiological studies (on about 100 children) do not suggest an increased risk of neurodevelopmental disorders or delays.
Međutim, trenutna epidemiološka ispitivanja (na približno 100 djece) ne ukazuju na povećani rizik od neurorazvojnih poremećaja ili kašnjenja u razvoju.
- Do not stop your treatment without your doctor's advice as this could increase your seizures.
• Nemojte prekinuti liječenje bez savjeta liječnika jer to može pojačati napadaje.
If you forget to take Levetiracetam Accord Contact your doctor if you have missed one or more doses.
Ako ste zaboravili uzeti Levetiracetam Accord Obavijestite liječnika ako ste zaboravili uzeti jednu ili više doza.
(monotherapy).
(monoterapija).
Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation).
Levetiracetam se koristi za oblik epilepsije u kojem napadaji započinju u jednoj strani mozga, ali se nakon toga mogu proširiti na veće područje u obje strane mozga (parcijalni napadaj sa ili bez sekundarne generalizacije).
PVC/Alu blister pack:
PVC/Al blister pakiranje:
When you will first start taking Levetiracetam Accord, your doctor will prescribe you a lower dose (500 mg each day) during 2 weeks before giving you the lowest general dose of 1000 mg.
Kad prvi put počnete uzimati Levetiracetam Accord, liječnik će Vam propisati manju dozu (500 mg svaki dan) tijekom 2 tjedna prije davanja najmanje uobičajene doze od 1000 mg.
The leaflet was last revised in (month/YYYY).
Ova uputa je zadnji puta revidirana u {mjesec/GGGG}
Pharmacotherapeutic group: antiepileptics, other antiepileptics ATC code: N03AX14.
Farmakoterapijska skupina: antiepileptici, ostali antiepileptici, ATK oznaka: N03AX14.
Therefore, the interaction of Levetiracetam with other substances, or vice versa, is unlikely.
Iz toga proizlazi da interakcija Levetiracetama s drugim tvarima, i obrnuto, nije vjerojatna.
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000).
Nuspojave su prikazane u padajućem nizu s obzirom na ozbiljnost i njihova učestalost je definirana na sljedeći način: vrlo često (≥1/10); često (≥1/100 i <1/10); manje često (≥1/1000 i <1/100); rijetko (≥1/10 000 i <1/1000) i vrlo rijetko (<1/10 000).
How to store Levetiracetam Accord Contents of the pack and other information
Kako čuvati Levetiracetam Accord Sadržaj pakiranja i druge informacije
What Levetiracetam Accord is and what it is used for What you need to know before you take Levetiracetam Accord How to take Levetiracetam Accord Possible side effects
Što je Levetiracetam Accord i za što se koristi Što morate znati prije nego počnete uzimati Levetiracetam Accord Kako uzimati Levetiracetam Accord Moguće nuspojave
Levetiracetam Accord is an antiepileptic medicine (a medicine used to treat seizures in epilepsy).
Levetiracetam Accord jest antiepileptik (lijek koji se koristi u liječenju epileptičkih napadaja).
Creatinine clearance (ml/min/1.73m2)
Klirens kreatinina (ml/min/1,73m2)
Prevalence is significantly higher in Japanese patients when compared to nonJapanese patients.
Prevalencija je značajno veća u japanskih bolesnika u usporedbi s bolesnicima koji nisu japanskog podrijetla.
What you need to know before you take Levetiracetam Accord
Što morate znati prije nego počnete uzimati Levetiracetam Accord
Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60 ml/min/1.73m2.
Stoga se preporučuje 50%-tno smanjenje dnevne doze održavanja ako je klirens kreatinina < 60 ml/min/1,73 m2.
Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents including levetiracetam.
Samoubojstvo, pokušaj samoubojstva te samoubilačke ideje i ponašanje bili su prijavljivani kod bolesnika liječenih antiepileptičkim lijekovima uključujući levetiracetam.
Should your doctor decide to stop your Levetiracetam Accord treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Accord.
Ako Vaš liječnik odluči prekinuti liječenje Levetiracetam Accordom, uputit će Vas kako postupno prekinuti liječenje Levetiracetam Accordom.
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1.
Preosjetljivost na djelatnu tvar ili neke druge pirolidonske derivae ili neku od pomoćnih tvari navedenih u dijelu 6.1.
This medicinal product does not require any special storage conditions.
- Ovaj lijek ne zahtijeva posebne uvjete čuvanja.
Levetiracetam is indicated as adjunctive therapy
Levetiracetam je indiciran kao dodatna terapija
In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69).
U studiji, koja je bila odraz kliničke prakse bilo je moguće prekinuti istodobno antiepileptičko liječenje u ograničenog broja bolesnika koji su odgovorili na dodatno liječenje levetiracetamom (36 od 69 odraslih bolesnika).
It is therefore recommended to adjust the maintenance daily dose of levetiracetam, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2).
Stoga se preporučuje prilagođavanje dnevne doze održavanja Levetiracetama s obzirom na klirens kreatinina u bolesnika s umjerenim i teškim oštećenjem bubrega (vidjeti dio 4.2).
The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 ml/min/kg) than for adults (0.96 ml/min/kg).
Farmakokinetički podaci ukazuju da je poluvijek života (5,3 h) kraći nego u odraslih (7,2 h), a prividni klirens (1,5 ml/min/kg) brži je nego u odraslih (0,96 ml/min/kg).
Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviuor as measured in a standardised and systematic way using a validated instrument (CBCL - Achenbach Child Behavior Checklist).
Rezultati ocjene funkcioniranja ponašanja i emocionalnog funkcioniranja uputili su na pogoršanje u smislu agresivnijeg ponašanja u skupini koja je uzimala levetiracetam, ocijenjenog na standardiziran i sistematičan način koristeći validirani instrument (CBCL - Achenbach Child Behavior Checklist).
Alopecia,eczema, pruritus,
Alopecija, ekcem, pruritis,
500 to 1, 500 mg twice daily 500 to 1,000 mg twice daily 250 to 750 mg twice daily 250 to 500 mg twice daily 500 to 1,000 mg once daily (2)
500 do 1500 mg dva puta na dan 500 do 1000 mg dva puta na dan 250 do 750 mg dva puta na dan 250 do 500 mg dva puta na dan 500 do 1000 mg jedanput na dan (2)
• severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], Quincke's oedema [swelling of the face, lips, tongue and throat]);
• tjelesne težine alergijske reakcije (DRESS, anafilaktička reakcija [teška i ozbiljna alergijska reakcija], angioedem [oticanje lica, usana, jezika i grla];
The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily.
Početna doza za dijete ili adolescenta od 25 kg treba biti 250 mg dva puta na dan uz maksimalnu dozu od 750 mg dva puta na dan.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranicama Europske agencije za lijekove http://www.ema.europa.eu.
Do not use this medicine after the expiry date which is stated on carton box and blister after EXP.
- Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake Rok valjanosti i „EXP”.
Other medicines and Levetiracetam Accord Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
Marketing authorization holder and manufacturer Marketing authorization holder Accord Healthcare S.L.U.
Nositelj odobrenja za stavljanje lijeka u promet i proizvođač: Nositelj odobrenja za stavljanje lijeka u promet Accord Healthcare S.L.U.
However subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline.
Međutim, u ispitanika koji su uzimali levetiracetam tijekom dugoročne, otvorene studije provedene praćenjem, u prosjeku nije bilo pogoršanja bihevioralnog i emocionalnog funkcioniranja; osobito nije bilo pogoršanja pokazatelja agresivnog ponašanja u odnosu na početno stanje.
What Levetiracetam Accord looks like and contents of the pack 250 mg:
Kako Levetiracetam Accord izgleda i sadržaj pakiranja 250 mg:
If you stop taking Levetiracetam Accord
Ako prestanete uzimati Levetiracetam Accord
At 3600 mg /kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies.
Pri dozi od 3600 mg/kg/dan samo je u jednoj od dvije EFD studije uočeno blago smanjenje fetalne težine povezano s marginalnim porastom varijacija kostura/malih anomalija.
In both population pharmacokinetic analyses, there was about a 20% increase of apparent clearance of levetiracetam when it was co-administered with an enzyme-inducing antiepileptic medicinal product.
U obje farmakokinetičke analize populacije prividni klirens levetiracetama se povećao za oko 20% kada se lijek davao istodobno s antiepileptikom koji inducira enzime.
Adverse reactions reported in clinical studies (adults, adolescents, children and infants> 1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency.
Nuspojave zabilježene tijekom kliničkih studija (odrasli, adolescenti, djeca i dojenčad starija od 1 mjeseca) ili iskustva nakon stavljanja lijeka u promet navedene su u sljedećoj tablici s obzirom na organski sustav i učestalost.
CLcr (ml/min) CLcr (ml/min/1.73 m2) = ---------------------------- x 1.73 BSA subject (m2)
CLcr (ml/min) CLcr (ml/min/1,73 m2) = ------------------------------ x 1,73 PT bolesnika (m2)
In all of the above cases levetiracetam oral solution should be used.
U svim tim slučajevima treba upotrijebiti oralnu otopinu levetiracetama.
Contains sunset yellow (E110).
Sadrži sunset yellow (E 110).
10 film-coated tablets 20 film-coated tablets 30 film-coated tablets 50 film-coated tablets 60 film-coated tablets 100 film-coated tablets 200 film-coated tablets 30 X 1 film-coated tablet 60 X 1 film-coated tablet 100 X 1 film-coated tablet
10filmom obloženih tableta 20 filmom obloženih tableta 30 filmom obloženih tableta 50 filmom obloženih tableta 60 filmom obloženih tableta 100 filmom obloženih tableta 200 filmom obloženih tableta 30 X 1 filmom obloženih tableta 60 X 1 filmom obloženih tableta 100 X 1 filmom obloženih tableta
• skin rash, which may form blisters and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme), a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (StevensJohnson syndrome), and a more severe form causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis).
• crvenilo kože koje može tvoriti mjehuriće i izgledati kao male mete (sa središnjim tamnim točkama okruženim bljeđim područjem i tamnim prstenom oko ruba) (erythema multiforme), jako rasprostranjen osip s mjehurma i kožom koja se ljušti, osobito oko usta, nosa, očiju i genitalija (Stevens-Johnsonov sindrom), i mnogo teži oblik koji uzrokuje ljuštenje kože na više od 30% površine tijela (toksična epidermalna nekroliza).
You should not drive or use machines until it is established that your ability to perform such activities is not affected.
Ne smijete voziti ili upravljati strojevima dok se ne utvrdi da uzimanje lijeka Levetiracetam Accord ne utječe na Vaše sposobnosti za to.
Height (cm) x ks CLcr (ml/min/1.73 m2) = ----------------------------------Serum Creatinine (mg/dl)
Visina (cm) x ks CLcr (ml/min/1,73 m2) = --------------------------------------kreatinin u serumu (mg/dl)
Film-coated tablet The tablet can be divided into equal halves
Tableta se može razdijeliti u jednake polovice.
Excipient with known effect: Each film-coated tablet contains 0.013 mg of sunset yellow FCF (E110)
Pomoćna tvar s poznatim učinkom: Jedna filmom obložena tableta sadrži 0,013 mg bojila sunset yellow FCF (E110).
The other strengths of Levetiracetam tablets do not contain this ingredient.
Levetiracetam tableta me sadrže ovaj sastojak.
Additionally, the tablets are also available in unit dose blister for the pack size of 30x1, 60x1 and 100x1 tablets.
Osim toga, tablete su također dostupne u blisterima djeljivim na jedinične doze za pakiranja od 30x1, 60x1 i 100x1 tableta.
Not all pack sizes may be marketed
Na tržištu se ne moraju nalaziti sve veličine pakiranje.
At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common.
Na početku liječenja ili nakon povećanja doze nuspojave, poput pospanosti, umora i omaglice, mogu se javiti češće.
In a pooled analysis, the percentage of patients who achieved 50% or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7%, 31.6% and 41.3% for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6% for patients on placebo.
Analizom zbirnih podataka utvrđeno je da je postotak bolesnika kod kojih je postignuto 50 %-tno ili više smanjenje od početne učestalosti djelomičnih napadaja tjedno uz konstantnu dozu (12/14 tjedana) bio 27,7% kod uzetih 1000 mg, 31,6% kod uzetih 2000 mg i 41,3% kod uzetih 3000 mg levetiracetama te 12,6% kod uzimanja placeba.
The patients were randomized to carbamazepine CR 400 - 1200 mg /day or levetiracetam 1000 - 3000 mg /day, the duration of the treatment was up to 121 weeks depending on the response.
Bolesnici su randomizirani za dobivanje 400 -1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 - 3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
The CLcr in ml/min/1.73 m2 may be estimated from serum creatinine (mg/dl) determination, for young adolescents,children and infants, using the following formula (Schwartz formula):
Klirens kreatinina u ml/min/1,73 m2 može se za mlade adolescente, djecu i dojenčad procijeniti iz vrijednosti serumskoga kreatinina (mg/dl) s pomoću sljedeće formule (Schwartzova formula):
• as an add-on to other antiepileptic medicines to treat: - partial onset seizures with or without generalisation in adults, adolescents, children and infants from one month of age; - myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy - primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in adults and adolescents from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).
• kao dodatna terapija uz druge antiepileptike u liječenju: - parcijalnih napadaja sa sekundarnom generalizacijom ili bez nje u odraslih, adolescenata, djece i dojenčadi od prvog mjeseca života - miokloničkih napadaja (kratki, iznenadni trzaji mišića ili skupine mišića) u odraslih i adolescenata starijih od 12. godine života s juvenilnom miokloničkom epilepsijom - primarno generaliziranih toničko-kloničkih napadaja (veliki napadaji, uključujući gibitak svijesti) u odraslih i adolescenata starijih od 12. godine života s idiopatskom generaliziranom epilepsijom (oblik epilepsije za koji se smatra da je genetski uvjetovan).